Jessica Chutter Joins PTC Therapeutics' Board to Enhance Strategic Vision and Growth

PTC Therapeutics Welcomes Jessica Chutter to Its Board of Directors

PTC Therapeutics, Inc. recently announces the appointment of Jessica Chutter to its Board of Directors, aiming to bolster its strategic vision within the biopharmaceutical landscape. Chutter brings over 40 years of experience in biotechnology investment banking, having previously served as Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley. Her extensive background encompasses involvement in approximately $80 billion in capital raises and $85 billion in strategic transactions. This wealth of experience positions her as a formidable addition to PTC’s governance team, which is currently focused on advancing the company’s innovative pipeline aimed at treating rare disorders.

Michael Schmertzler, the Chairman of the Board, articulates confidence in Chutter’s ability to contribute meaningfully to the company's strategic direction. He emphasizes her deep-rooted understanding of the biotechnology sector, particularly her proven track record in navigating complex financial landscapes. The Board, alongside PTC's management, seeks to utilize Chutter's skills to accelerate growth and enhance the company’s ability to address the needs of patients suffering from rare disorders. Her prior experience and established relationships within the industry are seen as integral components that can help PTC continue to transform and expand its market presence.

CEO Matthew B. Klein, M.D., echoes these sentiments by highlighting Chutter's past role as a trusted advisor and her substantive experience in building biotech companies. As PTC Therapeutics strives to develop differentiated medicines that meet unmet medical needs, Chutter’s vision aligns closely with the company's strategic objectives. Her enthusiasm for PTC’s journey indicates her commitment to not only sustaining existing growth but also spearheading new initiatives that can further establish PTC as a leader in the biotechnology sector.

In addition to this key appointment, PTC Therapeutics is steadfast in its mission to discover, develop, and commercialize innovative therapies for patients with rare diseases. The company continues to leverage its scientific expertise and comprehensive global infrastructure to optimize value for stakeholders in this niche yet impactful segment of healthcare.

The addition of Jessica Chutter to the Board underscores PTC Therapeutics’ commitment to enhancing its leadership capabilities as it navigates the complex landscape of biotechnology, positioning itself for robust future growth and ongoing innovation.